Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
AssigneesChelator LLC, Concat, Ltd.
InventorHarry S. Winchell
Life of this patent
Estimating the term…
Abstract
Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.
Claims7
A method for mitigating damage to the central nervous system caused by an ischemic stroke, seizure or trauma in a patient suffering therefrom, said method comprising administering to said patient an effective amount of a chelator that forms a complex with a member selected from the group consisting of cations of iron, copper and zinc, said complex having a thermodynamic equilibrium constant of 10−18 or less.
A method for mitigating damage to the heart caused by a heart attack or arrhythmia in a patient suffering therefrom, said method comprising administering to said patient an effective amount of a chelator that forms a complex with a member selected from the group consisting of cations of iron, copper and zinc, said complex having a thermodynamic equilibrium constant of 10−18 or less.
Dependencies are inferred from the claim text.